Compare EPR Properties (EPR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs GSK plc — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 22× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and GSK plc for 93 Days on average.
| EPR | GSK | |
|---|---|---|
Market Cap | $4.17B | $91.88B |
Volume | 992,716 | 7,730,529 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $61.18 |
52-Week Low | $48.71 | $43.24 |
Typical Hold Time | 46 Days | 93 Days |
Enterprise Value | $7.68B | $111.88B |
Dividend Yield | 6.84% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $55.03, up 1.76% today, with a bearish technical signal but oversold RSI suggesting potential reversal. The REIT reported strong Q2 2026 EPS beat ($0.79 vs. $0.745 expected) and maintains a high gross margin of 91.41%. Recent news highlights its 6.5% dividend yield and diversification into theme parks and experiential properties, though 2026 net income is projected to decline to $263 million.
The stock offers value with a forward P/E of 17.44 and consensus price target of $65.50, implying 19% upside. Key risks include declining 2026 profitability, high leverage exposure, and sensitivity to interest rates. Analyst sentiment is mixed with 32% buy ratings, but institutional buying and oversold conditions support a cautious bullish outlook for income-focused investors.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
